Resmed Stock

Resmed EBIT

The EBIT of Resmed (RMD) as of Jul 29, 2026 is 1.69 B USD. In the previous year, EBIT was 1.32 B USD — a change of 27.69% (higher).

EBIT

1.69 BUSD

YoY

27.69%

Last updated:

In 2026, Resmed's EBIT was 1.69 B USD, a 27.69% increase from the 1.32 B USD EBIT recorded in the previous year.

The Resmed EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B USD)
Date
EBIT (B USD)
Jan 1, 2023
1.13 base
Jan 1, 2024
1.32 base
Jan 1, 2025
1.69 base
Jan 1, 2026 (e)
2.07 base
Jan 1, 2027 (e)
2.18 base
Jan 1, 2028 (e)
2.33 base
Jan 1, 2029 (e)
2.50 base
Jan 1, 2030 (e)
2.83 base
YEAREBIT (B USD)
2030 est 2.83
2029 est 2.50
2028 est 2.33
2027 est 2.18
2026 est 2.07
2025 1.69
2024 1.32
2023 1.13
2022 0.98
2021 0.90
2020 0.81
2019 0.58
2018 0.54
2017 0.43
2016 0.43
2015 0.41
2014 0.41
2013 0.35
2012 0.29
2011 0.27
2010 0.24
2009 0.19
2008 0.14
2007 0.09
2006 0.13
Access this data via the Eulerpool API

Resmed Revenue

Resmed Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
4.22 B USD
1.13 B USD
897.56 M USD
Jan 1, 2024
4.69 B USD
1.32 B USD
1.02 B USD
Jan 1, 2025
5.15 B USD
1.69 B USD
1.40 B USD
Jan 1, 2026 (e)
5.65 B USD
2.07 B USD
1.64 B USD
Jan 1, 2027 (e)
5.95 B USD
2.18 B USD
1.78 B USD
Jan 1, 2028 (e)
6.34 B USD
2.33 B USD
1.95 B USD
Jan 1, 2029 (e)
6.81 B USD
2.50 B USD
2.08 B USD
Jan 1, 2030 (e)
7.70 B USD
2.83 B USD
2.38 B USD

Resmed Margins

Resmed stock margins

The Resmed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Resmed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Resmed.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
55.78 %
26.80 %
21.25 %
Jan 1, 2024
56.67 %
28.17 %
21.79 %
Jan 1, 2025
59.36 %
32.75 %
27.22 %
Jan 1, 2026 (e)
59.36 %
36.71 %
29.01 %
Jan 1, 2027 (e)
59.36 %
36.71 %
29.88 %
Jan 1, 2028 (e)
59.36 %
36.71 %
30.84 %
Jan 1, 2029 (e)
59.36 %
36.71 %
30.52 %
Jan 1, 2030 (e)
59.36 %
36.71 %
30.90 %

Resmed Stock analysis

What does Resmed do? ResMed Inc. is a global leading provider of medical devices for the treatment of sleep disorders and respiratory diseases. The company was founded in Australia by Peter Farrell, a former employee of the University of New South Wales, in 1989. Today, ResMed is headquartered in San Diego, California, and employs over 7,500 people worldwide. Business model: ResMed's business model is based on providing medical products and solutions for the treatment of sleep apnea and other respiratory diseases. The company develops and distributes masks, devices, and accessories that help patients breathe better and achieve restful sleep. ResMed also offers cloud-based software solutions and services to assist doctors and sleep labs in diagnosing and monitoring patients. Products and divisions: ResMed's product range can be divided into four main divisions: Sleep & Respiratory Care, Software as a Service (SaaS), Technologies, and Dental Solutions. Sleep & Respiratory Care: In this division, ResMed offers a wide range of masks, devices, and accessories for the treatment of sleep apnea and other respiratory diseases. The most well-known products include the AirSense and AirMini devices, equipped with Automatic Sleep Detection and AutoSet algorithm to optimize respiratory pressure. ResMed also offers a range of CPAP masks, nasal and full face masks, as well as nasal pillow masks. Software as a Service (SaaS): ResMed's cloud-based software solutions and services are offered under the brand AirView. They include diagnostic tools, patient monitoring systems, and analysis tools. AirView allows doctors to access their patients' medical data captured by ResMed devices and monitor this data in real-time. Technologies: ResMed's Technologies division focuses on the development of advanced sensors for respiratory and sleep monitoring. Products include the S+, a smart sleep tracking system that operates without direct body contact, and the Reveal-LTE, an implant for monitoring heart and respiratory rates in patients with heart failure. Dental Solutions: ResMed has also developed products for dentistry to assist patients with mild to moderate upper airway obstruction. Products include the Narval CC, a custom-made dental device for the treatment of snoring and sleep apnea, and the Tap Pap nasal pillow oral appliance, a non-invasive mouthguard. Conclusion: ResMed is a leading provider of medical devices and solutions for the treatment of sleep apnea and other respiratory diseases. The company offers innovative products and technologies that help patients breathe better and achieve restful sleep. ResMed's cloud-based software solutions enable doctors to monitor their patients' health in real-time and develop effective diagnosis and treatment strategies. With its wide range of products, innovation, and highly qualified team of scientists, engineers, and medical professionals, ResMed will continue to play an important role in the healthcare industry. Resmed is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Resmed's EBIT

Resmed's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Resmed's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Resmed's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Resmed’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Resmed stock

EBIT of Resmed is 1.69 B USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Resmed

All Key Metrics — Resmed